Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly slashes 2023 profit outlook despite weight-loss drug earnings boost

Eli Lilly's Mounjaro, a diabetes drug that is expected to received FDA approval for weight loss treatment, generated more than $1.4 billion in September quarter revenues.

Stock Index Futures Climb on Hopes of End to Fed Rate Hikes, Apple Earnings on Tap

Stock Index Futures Climb on Hopes of End to Fed Rate Hikes, Apple Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.50%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.70% this morning as market participants weighed the possible peak of the Federal Reserve’s historic tightening campaign and looked ahead to an earnings report from Apple.

Dow Jones Futures Rise: Market Rally Gains Steam On Fed Chief Powell's 'Decay'; Palantir Jumps

Dow Jones Futures Rise: Market Rally Gains Steam On Fed Chief Powell's 'Decay'; Palantir Jumps

Techs led futures higher, with Palantir and Roku among the big earnings winners. Fed chief Jerome Powell signaled no more rate hikes, fueling Wednesday's strong market rally.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Verve Stock Soars On $250 Million Eli Lilly Deal

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

Investors Business Daily

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

Investors Business Daily

Chart of the Day: Eli Lilly - Big Profits in Big Pharma

The Chart of the Day belongs to the pharmaceutical giant Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Investors Scurry To Buy 14 Soaring Stocks As Market Sells Off

Don't assume that all S&P 500 stocks are struggling. A small group are actually thriving, thank you.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Market Volatile After Powell Speech; These Economic Reports Are A Worry

Stock Market Volatile After Powell Speech; These Economic Reports Are A Worry

Powell said he is encouraged by the slowing trend in inflation but would not rule out more rate hikes.

Investors Business Daily

Is It Too Late To Buy Eli Lilly Stock?

Is It Too Late To Buy Eli Lilly Stock?

Eli Lilly stock has crushed the broader markets in the past 10 years. But should you buy LLY at current levels, given its lofty valuation?

Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds

Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds

A new study finds that the medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight

The Independent UK

Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review

Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review

The major indexes rallied for the week, but hit resistance at key levels amid weak stock market breadth. Novo Nordisk, JPMorgan, Exxon were in focus.

Investors Business Daily

Dow Jones Futures Rise: Market Rally At Key Levels As Inflation Data Looms; Novo Nordisk Soars

Dow Jones Futures Rise: Market Rally At Key Levels As Inflation Data Looms; Novo Nordisk Soars

The Nasdaq is just above its 50-day line with the CPI inflation report due. Novo Nordisk soared on news that slammed medtech stocks.

Investors Business Daily

9 'Unstoppable' Stocks Deliver Big Gains And No Pain To Investors

9 'Unstoppable' Stocks Deliver Big Gains And No Pain To Investors

Risk and reward are supposed to be attached at the hip for S&P 500 stocks. But a small group of stocks are delivering all gain and no pain.

Investors Business Daily

Novo Nordisk, Eli Lilly leap as Ozempic shows promise in kidney patient treatment

Novo Nordisk, Eli Lilly leap as Ozempic shows promise in kidney patient treatment

Ozempic, the diabetes treatment often prescribed for weight loss, is also proving highly effective in treating patients with chronic kidney disease.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Weight-Loss Drugs Aren't To Blame For The Snack Pullback. Pepsi Offers This Reason.

Weight-loss drugs aren't the reason for suppressed shopping cart spending in a shaky economy, Pepsi executives say.

Investors Business Daily

Dow Jones Futures Fall, Oil Prices Spike After Hamas Attack

Futures fell and crude oil prices spiked following the Hamas attack on Israel. Nvidia leads 11 stocks flashing buy signals after Friday's bullish upside reversal.

Investors Business Daily

The Point At Which IBD Stock Of The Day Eli Lilly Could Become Actionable Again

Eli Lilly is Friday's IBD Stock Of The Day. After announcing an acquisition, Eli Lilly stock is bounding off its 50-day moving average.

The Guardian - US

US nutrition panel’s ties to top food giants revealed in new report

Transparency group US Right to Know finds members linked to Nestlé, Coca-Cola and others, raising conflict-of-interest questions

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Rise: Jobs Report Due; Tesla Cuts Model 3, Y Prices Again

The jobs report is key for a struggling market rally attempt. Tesla cut Model 3 and Model Y prices again.

Investors Business Daily

Why Eli Lilly's $1.4 Billion Takeover Is A Boon For More Than Just Point Biopharma

Eli Lilly said Tuesday it will buy cancer specialist Point Biopharma Global for $1.4 billion, launching PNT stock to a two-year high.

Point Biopharma stock soars on $1.4B takeover bid from Eli Lilly

Eli Lilly will add to its growing oncology business with the $1.4 billion takeover of Point Biopharma Global

Investors Business Daily

These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs

After a run, stocks can offer a new buying opportunity with a pullback to the 50-day line. Novo Nordisk and 4 S&P 500 stocks have done that.

Investors Business Daily

7 Stocks Soar More Than 90% Even As Fed Hikes Rates

Who says higher interest rates are bad for S&P 500 stocks? A select group is thriving even as the Federal Reserve hikes.

Here's What $1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth Now

Eli Lilly stock has surged over 1,200% in the last 10 years. Here's why I remain bullish on this blue-chip healthcare stock right now.

The Conversation

Mounjaro: type 2 diabetes drug more effective than Ozempic to launch in the UK — here’s what you need to know

A new drug to treat type 2 diabetes has been approved for use) in the UK. Tirzepatide (sold under the brand name Mounjaro) could be available for prescription by early 2024 – subject to availability.

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

Bank of America

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

247,725 stories

103,823 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play